RVL PHARMA PLC (RVLP)
(Delayed Data from NSDQ)
$NA USD
0 (0.00%)
Updated Dec 31, 1969 06:00 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for RVL Pharmaceuticals PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 50 | 18 | 178 | 240 |
Cost Of Goods | NA | 9 | 4 | 74 | 112 |
Gross Profit | NA | 40 | 14 | 103 | 128 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 99 | 97 | 174 | 409 |
Income After Depreciation & Amortization | 0 | -59 | -83 | -70 | -281 |
Non-Operating Income | NA | 10 | 3 | 1 | 1 |
Interest Expense | NA | 3 | 3 | 14 | 18 |
Pretax Income | NA | -52 | -83 | -84 | -298 |
Income Taxes | NA | 0 | 0 | -5 | -27 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -52 | -83 | -80 | -271 |
Extras & Discontinued Operations | NA | 0 | 18 | 0 | 0 |
Net Income (GAAP) | NA | -52 | -65 | -80 | -271 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -42 | -65 | 23 | 60 |
Depreciation & Amortization (Cash Flow) | NA | 17 | 18 | 93 | 341 |
Income After Depreciation & Amortization | 0 | -59 | -83 | -70 | -281 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 89.80 | 67.35 | 60.65 | 52.37 |
Diluted EPS Before Non-Recurring Items | NA | -0.68 | -1.05 | -0.37 | 0.25 |
Diluted Net EPS (GAAP) | NA | -0.58 | -0.96 | -1.31 | -5.17 |
Fiscal Year end for RVL Pharmaceuticals PLC falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | 8.26 |
Cost Of Goods | NA | NA | NA | NA | 1.95 |
Gross Profit | NA | NA | NA | NA | 6.31 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 28.34 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -22.03 |
Non-Operating Income | NA | NA | NA | NA | -1.97 |
Interest Expense | NA | NA | NA | NA | 0.01 |
Pretax Income | NA | NA | NA | NA | -24.00 |
Income Taxes | NA | NA | NA | NA | -0.11 |
Minority Interest | NA | NA | NA | NA | 0.00 |
Investment Gains/Losses | NA | NA | NA | NA | 0.00 |
Other Income/Charges | NA | NA | NA | NA | 0.00 |
Income From Cont. Operations | NA | NA | NA | NA | -23.89 |
Extras & Discontinued Operations | NA | NA | NA | NA | 0.00 |
Net Income (GAAP) | NA | NA | NA | NA | -23.89 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | 99.37 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | -0.13 |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | -0.24 |